Characterization of *In Vivo* and *In Vitro* Drug Screening Models for Gaucher Disease Based on GBA-D409V-KI MICE


Tina Löffler, Livia Breznik, Irene Schilcher, Agnes Molnar-Kasza, Stefanie Flunkert, Manuela Prokesch, Birgit Hutter-Paier

QPS Austria GmbH, Parkring 12, 8074 Grambach, AUSTRIA

BACKGROUND

It is well-described that mutations in the human GBA (glucosylceramidase- β) gene and associated lowered glucosylceramidase-ß (GCase) activity, can cause Gaucher disease (GD). Next to the significance of GCase for GD, the enzyme is highly discussed as therapeutic target in Parkinson`s disease (PD) research. To study both diseases and test possible therapeutic agents in vivo, specific mouse models were generated. Here we characterize GBA-D409V-KI mice, that express the mutant D427V GBA protein which corresponds to the D409V mutation in the mature human GBA protein, for expression of typical GD and PD biomarkers. Additionally, a corresponding in vitro model, embryonic fibroblasts generated from GBA-D409V-KI mice, is validated by evaluation of after treatment GCase activity with the β –glucosidase inhibitor isofagomine.

RESULTS




MATERIALS and METHODS

Liver samples and brains hemispheres of 4 to 12 months old homo- (tm/tm) and heterozygous (tm/wt) GBA-D409V-KI mice as well as age-matched wild type littermates (wt/wt) were assessed for GCase activity using the 4-MUG assay. Each sample was analyzed in duplicates and a third replicate including 1 mM CBE was used to subtract the GBA1 unspecific signal.

An aliquot of the hemisphere homogenate from 12

Figure 1. GBA1 activity in liver and brain samples of GBA-D409V-KI mice with age. GBA1 activity as μ M/h in liver (A) and brain samples (B) of homo- (tm/tm) and heterozygous (tm/wt) GBA-D409V-KI mice as well as age-matched wild type littermates (wt/wt) at 4, 6, 8 and 12 months of age; n=12 per group. Two-way ANOVA with Bonferroni's *post hoc* test; mean + SEM; *p<0.05; **p<0.01; ***p<0.001.

Soluble and Insoluble Cerebral *α*-synuclein



Soluble Figure insoluble and 2. α -synuclein in brain samples of 12 **months old animals.** Murine α -synuclein (mSCNA) in soluble (A) and insoluble (B) brain fractions of homo- (tm/tm) and (tm/wt) GBA-D409V-KI heterozygous mice as well as age-matched wild type littermates (wt/wt) at 12 months of age; n=12 per group. Two-way ANOVA with Bonferroni's post hoc test; mean + SEM; *p<0.05.

months old animals was used for extraction of soluble and Triton X-100 insoluble proteins and subsequently analyzed for murine α-synuclein level with a self-established immunosorbent assay based on the Mesoscale Discovery (MSD) platform.


The corresponding *in vitro* model, mouse embryonic fibroblasts (MEFs) generated from homo- or heterozygous GBA-D409V-KI E14 embryos or the wild type littermates, were validated by testing the effects of isofagomine on GCase activity normalized to viability.

GCase activity was determined with an on-cell 4-MUG assay, viability was assessed using the crystal violet assay. Data are given as relative fluorescent units (RFU) of 4-MUG assay normalized to optical density (OD) values derived from the crystal violet assay.

Mouse Embryonic Fibroblasts

Figure 3. GCase activity in mouse embryonic fibroblasts (MEFs) of different genotypes treated with vehicle (VC) or Isofagomine (IFG). Mouse embryonic fibroblasts were isolated from homo- (tm/tm) and heterozygous (tm/wt) GBA-D409V-KI E14 embryos as well as age-matched wild type littermates (wt/wt). Cells were cultivated in 96-well plates and treated with either vehicle (0.1 % DMSO) or 20 μ M isofagomine for 7 days. Thereafter, cells were subjected to either an adapted on-cell 4-MUG or crystal violet assay. Data are given as relative fluorescent units (RFU) of 4-MUG assay normalized to optical density (OD) values derived from crystal violet assay; n=5 per group. Two-way ANOVA with Bonferroni's *post hoc* test; mean + SEM; *p<0.05; **p<0.01.

MEF on-cell GCase assay







In summary, we provide a baseline characterization of GD and PD biomarkers in GBA-D409V-KI

mice and corresponding MEFs. Genotype-specific reduction of GCase activity is reliably present

in both models. MEFs are a suitable in vitro screening tool before selected compounds are

tested in the corresponding in vivo mouse model.